3 results
The primary objective of this study is to assess the overall safety and tolerability of subcutaneous (SC) trastuzumab using SID (Singel Injection Device) in HER2-positive eBC (early Breast Cancer) patients self-administered at home under supervision…
To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…
Primary Objectives:* To study early (1 week after start of cCRT) and late changes (after finishing cCRT) in durvalumab (MEDI4736) uptake in tumor and metastatic lymph nodes during cCRT * To study early and late changes in durvalumab (MEDI4736)…